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ABSTRACT – Promotion of research is a key strategy of the 
National Health Service (NHS). Currently, many patients are 
not afforded the opportunity to participate in clinical studies. 
A register of research-interested patients has the potential to 
maximise inclusivity. We have established a register of 
research-interested patients with Parkinson’s disease within 
the South West of England, with pragmatic inclusion criteria 
and multiple recruitment routes. We undertook an analysis of 
the register, investigation of its utility as a recruitment tool 
and a survey of recruiters. There were 529 active participants; 
30% were self-referred and 70% were recruited by a healthcare 
practitioner. Response rate to annual questionnaires was 
86.5%. Staff time required for pack preparation, recruitment 
and data entry was 15 min per new recruit and 5 min per 
follow-up questionnaire. In total, 85% of recruiters viewed the 
register positively. A single mailing to participants resulted in 
a recruitment rate that significantly exceeded that achieved 
by traditional recruitment methods.
KEY WORDS: Parkinson’s disease register, registry, recruitment 
tool
Introduction
Research-active organisations experience better patient out-
comes1 as well as other benefits,2 compared with centres which 
are not research active. The promotion and conduct of research 
are core National Health Service (NHS) functions.3 However, 
many patients are not afforded the opportunity to participate in 
clinical studies. Limitations to the involvement of patients with 
Parkinson’s disease (PD) in clinical studies are disease-specific 
and reflect the inherent difficulties in conducting clinical studies 
in older people.4 Traditional recruitment relies on face-to-face 
contact between patient and recruiter and generally occurs in a 
secondary care setting, community-based cohorts being more 
difficult to recruit. Therefore, studies involving such patients are 
limited. In addition, the demands of a busy clinical service might 
limit the participation of interested healthcare practitioners 
(HCPs). As a result, trial data might be generated from a non-
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representative patient population. One means of overcoming 
these challenges is to establish a register of research-interested 
patients. As well as facilitating recruitment, registers can inform 
clinical trial design.5 Several PD registers have previously been 
established6–12 and used to provide information on epidemi-
ology, clinical features and therapeutics.
In this article, we describe our experience of establishing the 
Parkinson’s Register of the Dementias and Neurodegenerative 
Diseases Research Network (PRO-DeNDRoN), an inclusive reg-
ister of research-interested patients with PD within the South 
West of England. The inclusion criteria and recruitment routes 
are broad, the information collected being the minimum required 
to facilitate study recruitment. Further determination of indi-
vidual eligibility for specific studies is then performed by inves-
tigators as part of the screening process. Here, we analyse the 
register three years after it was initiated, with the primary aim of 
demonstrating the pitfalls and benefits of establishing the reg-
ister, as well as its utility as a recruitment tool. We also demon-
strate that the model used enables the register to fulfil its aims in 
a manner that is pragmatic and resource efficient. 
Methods
Overview
Register development and management is overseen by the PRO-
DeNDRoN coordinating team. A steering committee independ-
ently oversees the running of the project, monitors recruitment 
rate and reviews studies applying to use the register. The com-
mittee includes representatives of each of the main recruitment 
sites as well as a patient and carer representative. Ethical approval 
for the register was obtained in August 2007, with a substantial 
amendment being approved in August 2008 following an adjust-
ment to the consent form. All register participants were required 
to re-consent to remain on the register.
Database design
A bespoke database for the register is hosted on a Structured 
Query Language (SQL) server within the University of Plymouth 
(UoP) and is backed up daily. Access is password protected and 
restricted to the database development team. Front-end access is 
web based to enable online access at different levels. Data are 
entered into the database from patient-completed question-
naires by the study administrator. Data input and utilisation of 
the database informs its continued development.
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Survey of register recruiters
We conducted a web-based survey of HCPs who might have 
recruited to the register to ask for their feedback, specifically 
regarding ease of recruitment, any concerns that they or their 
patients might have and their impression of register utility.
Results
Demographics of recruits
At the time of register analysis (October 2010), there were 529 
active participants (589 recruits, 60 withdrawn). There were 327 
(61.8%) men and 202 (38.2%) women. Mean age at time of 
consent was 69.9 yr and, at time of register analysis, 71.4 yr. 
Mean disease duration at the time of recruitment was 7.4±6 yr 
from symptom onset, 6.5±5.7 yr from first consultation with a 
general practitioner and 5.7±5.4 yr from diagnosis.
Routes of referral and recruitment
Recruitment packs were distributed either directly to patients 
following self-referral (n=262, of which 177 (67.5%) were 
returned) or HCPs for distribution (n=1,246, of which 412 
(33%) were returned). It is not possible to determine how 
many packs were distributed by HCPs and not returned. In 90 
instances, the consent form was not fully completed and had to 
be returned to the patient; in total, 75 forms were eventually 
returned fully completed. Approximately half of the incom-
plete forms were lacking a patient signature. In 22% of cases, 
the last box (‘I consent to take part in the study’) on the con-
sent form was not initialled. The overall response rate to 
annual questionnaires was 86.5%, although this reduced with 
time (Table 1). 
Diagnosis of recruited patients
A diagnosis of PD was assumed in initial recruits (n=214); a 
question investigating this in more detail was added to amended 
versions of the baseline questionnaire (Table 2). Of the 529 
recruits who provided diagnostic information, 92% had a base-
line diagnosis of PD (or were assumed to have PD), 4.2% had 
possible or probable PD, and 2.1% had Parkinsonism or 
Parkinson Plus syndrome. The proportions in those who pro-
vided this information in their 24-month questionnaire (n=127) 
were 83%, 2.4% and 5.5% respectively; 20 (15.7%) had a 
changed diagnosis from month 12 (Table 3), and 23 (18.1%) 
from baseline.
Non-pharmacological therapies
The details of non-drug therapies, both formal and informal, 
being accessed by patients are detailed in Table 4. The most 
common was physiotherapy (20% at baseline, 19% at month 12 
and 17.2% at month 24).
Participating sites and recruitment
The project was initiated in September 2007 in the peninsula 
of Devon and Cornwall in the South West of England and was 
extended in November 2009 to cover the whole of the South 
West DeNDRoN region. The recruitment strategy includes 
self-referral by either telephone or returning a reply slip from 
a flyer, recruitment in clinic by an HCP or research nurse, or 
recruitment at a local PD meeting. Personal details of new 
referrals are kept for 90 days, following which they are 
removed from the database if the consent form has not been 
returned.
The inclusion criteria are as follows:
must be more than 18 years of age• 
must reside within the South West DeNDRoN region• 
must have had a clinical diagnosis of PD• 
must be capable of giving fully informed consent.• 
There are no exclusion criteria.
Interested patients are provided with an information sheet, 
consent form, baseline questionnaire and freepost envelope to 
return the documentation to the coordinating centre. Patients 
consent to their details being kept on the database, their med-
ical records being consulted when necessary, being contacted in 
the future regarding studies for which they might be eligible, 
and for their anonymised data to be shared with local authori-
ties for the purpose of service development. The questionnaire 
asks for details regarding demographics, disease duration, 
diagnosis and therapies (pharmacological and non-pharmaco-
logical). The register is updated on an annual basis using a 
postal questionnaire. Patients and referring clinicians receive 
an annual newsletter giving details of clinical research activity 
in the region.
Register utilisation by researchers
The procedure for allowing researchers access to the register 
comprises a feasibility screen, steering committee approval and 
letters of invitation being sent to eligible patients by the PRO-
DeNDRoN team, with reply slips to be sent to the researchers. 
Researchers are sent anonymised data informing them of which 
patients have been sent letters. Researchers confirm who has 
been assessed and/or recruited to their study, thereby preventing 
patients from being recruited to too many or conflicting studies. 
This information also facilitates monitoring of recruitment 
levels and assessment of register utility. 
Register utility
We conducted an initial study of utilisation of the register in 
association with the Cure Parkinson’s Trust (CPT). The register 
has also been used to recruit to two further studies: a sample 
collection study and a questionnaire-based study.
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    Table 1. Response rate to questionnaires.
Total sent Total returned
Response 
rate (%)
Total number of 
questionnaires 
sent
1,152 991 86.5
Baseline 589 585 99.3
Month 12 330 260 78.8
Month 24 233 146 62.7
   Table 2. Diagnosis at baseline and follow-up.
Diagnosis Baseline (%) Month 12 (%) Month 24 (%)
Nulla 214 (40) 105 (83)
Parkinson’s 
disease (PD)
275 (52) 182 (88.3) 3
Possible or 
probable PD
22 4 78.8
Parkinsonism or 
Parkinson’s plus 
syndrome
11 7 7
Not sure 4 7 4
Other 3 6 8
No response 56 54 19
Total 585 260 146
aNull indicates the change in questionnaire, presumed to equal PD.
Table 3. Details of change in diagnosis between months 12 
and 24.
Month 12 diagnosis Month 24 diagnosis Total
Parkinson’s disease (PD) Other 3
Parkinsonism or 
Parkinson Plus 
syndrome
4
Not sure 1
Possible or probable PD 1
Parkinsonism or 
Parkinson Plus syndrome
Other 1
PD 2
Not sure 1
Other Parkinsonism or 
Parkinson Plus 
Syndrome
1
PD 1
Possible or probable PD Not sure 1
PD 1
Not sure PD 2
Possible or probable PD 1
Table 4. Details of non-drug therapeutic resources utilised by 
patients.
Baseline Month 12 Month 24
Number of participant 
responses recorded
546 of 585 228 of 260 128 of 146
Total responses listed 611 246 146
None/Not answered 383 162 88
Total number of 
treatments listed
228 84 58
Physiotherapy 109 43 22
Speech and language 
therapy
48 14 12
Occupational therapy 15 6 3
Massage 3 4 2
Acupuncture 2 0 1
Reflexology 4 1 1
Other: 47 16 17
Exercise 18 5 7
Pilates and/or yoga 4 1
Tai Chi 1
Deep brain stimulation 4 1 1
Podiatrist 1 1 1
Other medication 
assistance
2
Counselling 1 2 1
Education 1
PD nurse specialist 3 1
Botulinum toxin clinic 1 1
Chiropractor and/or 
osteopath
4 1
Memory clinic and/or 
support group
2
Lip strengthener 1
Bone density scan 1
Alexander Technique 2 1
Craft 1
Hearing aid 1
Reiki 1
Dietician 2
House alterations 2
Other assistance 2 1
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Withdrawals from the register 
In total, 40 men and 20 women had withdrawn from the register, 
representing approximately 10% of the recruits of each sex. The 
average duration on the register and the reason for withdrawal are 
given in Table 5. In total, 68% of withdrawals were because of 
either death of the patient or failure to re-consent. This was 
reflected in the annual withdrawal rate, which was higher in 2009 
(10%), probably precipitated by the change in consent form, com-
pared with 2008 (3.3%) and the first 10 months of 2010 (1.9%).
Register utilisation
In our initial feasibility assessment, 256 participants were 
approached with a single mailing to take part in the CPT pilot, 
seeking patients who had a follow-up appointment with their 
PD practitioner within the following eight weeks. In total, 33% 
did not respond, 45 (17.6%) stated that they did not wish to take 
part and 127 (49.6%) expressed a desire to participate. Of these 
127, 45 completed the pilot within the required timeframe and a 
further 10 shortly thereafter. By comparison, another UK centre 
used traditional face-to-face recruitment in clinic over a four-
week period. Approximately 30 patients were approached, of 
whom six completed the pilot.
The register was subsequently used for recruitment to a 
sample collection study in Cornwall. Traditional recruitment 
methods had resulted in five patients being recruited in the six 
months before using the register. In total, 113 patients on the 
register were approached by a single mailing to take part in the 
study in March 2011; 91 responded positively (80.5%), 61 of 
whom had been recruited by October 2011 (54% of those 
approached). A questionnaire-based study also utilised the reg-
ister for recruitment in April 2011, when the number of people 
on the register was greater than that at the time of analysis. In 
total, 627 patients were approached by a single mailing, of whom 
358 (57%) expressed interest in the study, with 295 finally being 
recruited (47% of those approached). 
Survey of PD practitioners
A web-based survey was emailed to 59 PD practitioners, com-
prising geriatricians and neurologists, research nurses and PD 
specialist nurses. The overall response rate was 51% (n=30). In 
total, 63% of responders reported recruiting to, or arranging 
recruitment to the register. Of the 11 responders who had not 
recruited to the register, 45% cited lack of appropriate paper-
work, 36% lack of time in clinic, 18% forgetting about the register 
in the clinic setting and 36% being unaware of the register.
Recruitment mainly occurred in clinic with the primary 
method of recruitment being for the patient to be given a 
recruitment pack (70%). Other methods included passing the 
patient’s details to the research nurse (55%) or the PRO-
DeNDRoN team (20%). The time taken to recruit patients was 
reported as 0–5 min by 75% and 5–10 min by 25% of recruiters. 
One-third of respondents had experienced patients refusing to 
take part in the register, for reasons including lack of interest in 
research, unwillingness to complete questionnaires, concerns 
about data access (one patient) and struggling to come to terms 
with their diagnosis. Three respondents had received feedback 
from patients about the register, namely that they appreciated 
the opportunity to take part in research.
Of the respondents, 85% felt that the register was a useful 
means of facilitating research and providing data for planning of 
service provision. However, concern was expressed over access to 
data, as well as the extent to which patients would be approached 
to take part in studies for which their treating physician would 
deem them unsuitable. Suggestions for improvement included 
development of a website for patients to register their interest 
and ensuring involvement of local practitioners in recruitment 
to potential studies.
Discussion
Research as a core NHS activity is receiving increasing recogni-
tion within the UK.2 Centrally funded infrastructure has been 
developed to assist with delivering research opportunities to all 
patients within the NHS. Despite this, many patients with PD are 
not afforded the opportunity to take part in clinical studies. We 
have established a register of research-interested patients with PD 
in a resource-efficient manner and have demonstrated that it can 
successfully be used as a recruitment tool. Most practitioners 
require less than 5 min to discuss the project with potential par-
ticipants. Total staff time required for pack preparation, recruit-
ment and data entry is 15 min for each new recruit and 5 min for 
each follow-up questionnaire. Our experience of register utilisa-
tion has demonstrated that a single mailing to participants can 
result in a final recruitment rate that significantly exceeds that 
achieved by traditional face-to-face recruitment.
A common concern with regard to registers is the need to 
balance patient privacy with investigator access to patients.13 
Such concerns have been highlighted by both patients and cli-
nicians participating in our register. To minimise these con-
cerns, it is explicit that no patient details are shared with 
Table 5. Duration on register and reason for withdrawal.
Reason for withdrawal Number Time on 
register (mo) 
mean ± SD
Age at 
withdrawal 
(yr) mean ± SD
Total 60 76.6±9.2
Re-consent 22 17.6±3.7
Deceased 19 18.1±7.8 81.7±4.7
Moved away 2 18.5±7.8
Unknown 11 11.9±8.1
Other: 6 6.3±7.4
     Duplicates 2
     Deterioration 3
      Only has Parkinson’s 
disease in legs
1
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researchers, unless the patients themselves return the reply slip 
to the investigator.
Difficulties of recruiting to the register
Recruitment rate following self-referral was 67.5%. It was not 
possible to determine active recruitment figures from our data. 
However, in some centres, there was insufficient time in clinic 
for recruitment by HCPs. In others, physicians wished to act as 
‘gatekeepers’ for research involving their patients. This phenom-
enon is well demonstrated in trials involving older people,14 
despite evidence that patients themselves are willing to partici-
pate in clinical studies.15 Nevertheless, it has equally been dem-
onstrated that endorsement of a study by the patient’s own 
physician can be a powerful recruitment tool.16 By adjusting 
paperwork to reflect local ownership of the register, and including 
representatives from each of the sites on the steering committee, 
we were able to overcome these misgivings.
Difficulties with retention
We found a reduction in response rate to the annual question-
naires over the 3 years. The problem of attrition in long-term 
studies involving older people is well documented, factors 
including being in poorer health and cognitive impairment.17 
Web-based access to details of their own patients on the register 
could provide clinicians with an opportunity to send a reminder 
if a questionnaire has not been returned.
Diagnosis
A clinical diagnosis of PD carries with it a degree of uncertainty, 
with studies estimating correct diagnosis in 83% of cases in a 
community setting,18 82% of cases in secondary care19 and 91% 
in a specialist movement disorder clinic.20 A previous commu-
nity-based PD registry was able to confirm the diagnosis in 78% 
of registrants.11 We found a self-reported rate of PD diagnosis in 
respondents of 92% at baseline, 88% at month 12 and 83% at 
month 24, probably reflecting the overdiagnosis of clinically 
uncertain cases at presentation.21 Despite 30% of participants 
self-referring to the register, all patients were being seen in sec-
ondary care, either by a neurologist (40%) or a geriatrician with 
a specialist interest in movement disorders (60%). Therefore, 
our diagnosis figures are consistent with those previously 
reported for secondary care. Although these figures could be 
regarded as limiting, the diagnostic inaccuracies are offset by the 
potential for inclusivity. Studies utilising the register will have 
their own screening procedures to ensure eligibility. There is also 
the facility to scrutinise patients’ medical records to verify diag-
nostic information.
Register benefits 
We are able to extract data that might be of value in planning 
future research initiatives and service developments. For example, 
the delay between symptom onset and diagnosis might represent 
an opportunity for education of patients and GPs. The identifica-
tion of alternative resources being utilised by patients can facilitate 
studies focussing on particular interventions and inform planning 
of local service provision. Finally, the register provides a means of 
increasing overall research awareness among patients and HCPs.
Planned register improvements 
We have identified several areas of potential improvement, 
including the visual layout of the consent form to increase accu-
racy of completion, development of web-based access for expres-
sion of interest and expansion of our recruitment strategy to 
include primary care and patients with cognitive impairment.
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